GlassScriptPhysician profile
John D Gordon
NPI 1831158351
$4,129.44
in general payments reported to CMS, 2019-2025
26 companies · $1,234 in 2025
The $1,234 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $526 · 2022: $557 · 2023: $703 · 2024: $1,110 · 2025: $1,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,968 · Consulting Fee: $44.47 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,968.32 |
| Consulting Fee | $44.47 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $864.41 | 2021-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $841.30 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Amgen INC. | $466.70 | 2022-2025 | Tezspire, Actimmune |
| Takeda Pharmaceuticals U.S.A., INC. | $339.79 | 2021-2025 | Cuvitru, Hyqvia, Eohilia |
| Genzyme Corporation | $333.93 | 2021-2025 | |
| Pfizer INC. | $203.42 | 2021-2025 | |
| Csl Behring | $168.19 | 2021-2025 | Haegarda, Hizentra |
| Novartis Pharmaceuticals Corporation | $157.50 | 2021-2025 | |
| Optinose US, INC. | $140.52 | 2021-2025 | |
| Pharming Healthcare, INC. | $86.75 | 2023-2024 | Ruconest |
| Regeneron Healthcare Solutions, INC. | $84.81 | 2021-2024 | Dupixent |
| Genentech USA, INC. | $67.26 | 2023-2025 | Xolair |
| Biocryst US Sales Co., LLC | $57.54 | 2024-2025 | Orladeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.48 | 2021 | |
| Adma Biomanufacturing LLC | $44.47 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $31.45 | 2021-2023 | |
| Organon LLC | $30.51 | 2025 | |
| Horizon Therapeutics Plc | $23.00 | 2022 | |
| Blueprint Medicines Corporation | $20.63 | 2023 | Ayvakit |
| Alk-Abello, INC | $19.60 | 2023 | Odactra, Ragwitek, Grastek |
| Aimmune Therapeutics, INC. | $17.74 | 2021 | |
| Incyte Corporation | $17.65 | 2022 | |
| Grifols USA, LLC | $16.15 | 2024 | Xembify |
| Octapharma USA, INC. | $15.90 | 2023 | Cutaquig |
| Lilly USA, LLC | $15.50 | 2025 | Taltz, Ebglyss |
| Teva Pharmaceuticals USA, INC. | $14.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.